Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipients

Craig Collins, Lam T. Khuat, Gail D. Sckisel, Logan V. Vick, Christine M. Minnar, Cordelia Dunai, Catherine T. Le, Brendan D. Curti, Marka R. Crittenden, Alexander Merleev, Quan Z. Sheng, Nelson J. Chao, Emanual Maverakis, Spencer R. Rosario, Arta M. Monjazeb, Bruce R. Blazar, Dan L. Longo, Robert J. Canter, William J. MurphyFrontiers in Immunology 2024 · DOI

TL;DR

Systemic immunostimulation, like that used in cancer therapy or viral infections, can cause a temporary but significant shrinking of the thymus, driven by stress hormones (glucocorticoids). While this effect is reversible in young and middle-aged individuals, it appears to be permanent in older recipients, potentially impacting their immune system's ability to respond to new threats.

What Problem Does This Paper Address?

The thymus is a critical organ for developing "naïve" T cells, which are essential for a robust immune response. As we age, the thymus naturally shrinks (involution), leading to a reduced output of these crucial cells and a shift towards "memory" T cells. While various stressors like radiation or inflammation can also cause temporary thymic involution, the impact of modern immunostimulatory cancer therapies on the thymus and naïve T cell production hasn't been fully understood. This paper investigates how these powerful therapies, and even acute viral infections, affect the thymus, particularly in the context of aging, and whether the body's stress response plays a key role.

Methods

The researchers employed a multi-pronged approach using both mouse models and human patient data.

  • Mouse Models:
    • Immunotherapy: Mice were treated with high-dose Interleukin-2 (HD IL-2) and/or agonistic anti-CD40 antibodies, common components of cancer immunotherapy.
  • Viral Infection: Mice were infected with a sub-acute dose of murine cytomegalovirus (MCMV).
  • Adrenalectomy: To isolate the role of stress hormones, some mice had their adrenal glands removed (adrenalectomized, adx) to prevent glucocorticoid production. Control mice underwent sham surgery.
  • Aging Studies: Mice of different age groups (young, middle-aged, and aged) were used to assess the impact of age on thymic recovery.
  • Analysis: Thymic cellularity, T cell populations (naïve, memory), serum cytokine levels, and serum glucocorticoid (corticosterone) levels were measured using flow cytometry, ELISA, and RNA sequencing.
  • Human Studies:
    • Clinical Trial Data: Blood samples from cancer patients receiving HD IL-2 therapy were analyzed.
  • Analysis: T cell phenotypes (naïve vs. memory), serum cortisol levels, and T-cell receptor excision circles (TRECs) – a marker of recent thymic emigrants – were measured.

Datasets

Not explicitly discussed as datasets for training/evaluation in the traditional machine learning sense. The study utilizes:

  • Mouse experimental data: Collected from various experimental groups as described in the "Methods" section.
  • Human clinical trial data: Blood samples from cancer patients undergoing HD IL-2 therapy.

Key Insights and Ideas

  • Glucocorticoids are the primary drivers of thymic involution: The study strongly suggests that stress hormones (glucocorticoids) are the main culprits behind the thymus shrinking during immunostimulation or infection, rather than pro-inflammatory cytokines alone. Adrenalectomized mice, unable to produce these hormones, were protected from thymic involution.
  • Thymic rebound is age-dependent: While young and middle-aged mice showed a remarkable "rebound" where their thymus grew even larger than normal after the initial involution, aged mice failed to recover, showing prolonged thymic shrinkage.
  • Human data mirrors mouse findings: Cancer patients receiving HD IL-2 therapy showed increased cortisol levels, a decrease in naïve T cells, and reduced TRECs, mirroring the thymic involution observed in mice.
  • Aging exacerbates the problem: Aged mice not only experienced more severe thymic involution but also failed to regain naïve T cells, leading to a further skewing of their immune system towards memory cells.

Key Results

  • Acute Thymic Involution: Systemic immunostimulation (HD IL-2, anti-CD40/IL-2) and MCMV infection in mice led to a rapid and significant decrease in thymic cellularity, particularly in the double-positive T cell population.
  • Elevated Glucocorticoids: These treatments were associated with a marked increase in serum corticosterone levels in mice and cortisol levels in humans.
  • Naïve T Cell Reduction: Both mice and humans showed a decrease in peripheral naïve T cells following these interventions.
  • Transient Rebound in Young/Middle-Aged: Young and middle-aged mice exhibited a significant thymic rebound hyperplasia after the stimulus was removed, with thymocyte numbers exceeding control levels.
  • Impaired Rebound in Aged: Aged mice (22-24 months) did not show any signs of thymic rebound and had prolonged deficits in naïve T cells.
  • Adrenalectomy Protection: Adrenalectomized mice were significantly protected from immunotherapy- and MCMV-induced thymic involution, despite experiencing higher inflammatory cytokine responses.
  • Human TREC Reduction: Cancer patients on HD IL-2 showed reduced TREC levels, indicating impaired recent thymic output.

Limitations and Future Work

  • Mechanistic Dissection: The authors acknowledge a lack of detailed mechanistic dissection in their studies, particularly regarding the precise pathways by which glucocorticoids induce apoptosis. Future work could focus on this.
  • Clinical Extrapolation: While human data supports the findings, the authors note that direct extrapolation from mouse models to clinical practice is complex due to differences in genetics, age, and disease states.
  • Combined Therapies: The study primarily focused on single or combined immunotherapy regimens. The effects of these regimens in combination with other conventional cancer therapies (chemotherapy, radiation) need further investigation.
  • Other Stressors: The role of other factors like sex hormones, obesity, and psychological stress on thymic function warrants further exploration.
  • Aged Rebound: While aged mice did not show rebound in this study, the authors suggest that a delayed recovery might still be possible and warrants further investigation at later time points.
  • Modeling Limitations: The current models for studying glucocorticoid effects have limitations. The authors suggest that a Cre-lox system to specifically eliminate endogenous glucocorticoids would be ideal for future research.

Summary updated

Abstract

The thymus is the central organ involved with T-cell development and the production of naïve T cells. During normal aging, the thymus undergoes marked involution, reducing naïve T-cell output and resulting in a predominance of long-lived memory T cells in the periphery. Outside of aging, systemic stress responses that induce corticosteroids (CS), or other insults such as radiation exposure, induce thymocyte apoptosis, resulting in a transient acute thymic involution with subsequent recovery occurring after cessation of the stimulus. Despite the increasing utilization of immunostimulatory regimens in cancer, effects on the thymus and naïve T cell output have not been well characterized. Using both mouse and human systems, the thymic effects of systemic immunostimulatory regimens, such as high dose IL-2 (HD IL-2) with or without agonistic anti-CD40 mAbs and acute primary viral infection, were investigated. These regimens produced a marked acute thymic involution in mice, which correlated with elevated serum glucocorticoid levels and a diminishment of naïve T cells in the periphery. This effect was transient and followed with a rapid thymic "rebound" effect, in which an even greater quantity of thymocytes was observed compared to controls. Similar results were observed in humans, as patients receiving HD IL-2 treatment for cancer demonstrated significantly increased cortisol levels, accompanied by decreased peripheral blood naïve T cells and reduced T-cell receptor excision circles (TRECs), a marker indicative of recent thymic emigrants. Mice adrenalectomized prior to receiving immunotherapy or viral infection demonstrated protection from this glucocorticoid-mediated thymic involution, despite experiencing a substantially higher inflammatory cytokine response and increased immunopathology. Investigation into the effects of immunostimulation on middle aged (7-12 months) and advance aged (22-24 months) mice, which had already undergone significant thymic involution and had a diminished naïve T cell population in the periphery at baseline, revealed that even further involution was incurred. Thymic rebound hyperplasia, however, only occurred in young and middle-aged recipients, while advance aged not only lacked this rebound hyperplasia, but were entirely absent of any indication of thymic restoration. This coincided with prolonged deficits in naïve T cell numbers in advanced aged recipients, further skewing the already memory dominant T cell pool. These results demonstrate that, in both mice and humans, systemic immunostimulatory cancer therapies, as well as immune challenges like subacute viral infections, have the potential to induce profound, but transient, glucocorticoid-mediated thymic involution and substantially reduced thymic output, resulting in the reduction of peripheral naive T cells. This can then be followed by a marked rebound effect with naïve T cell restoration, events that were shown not to occur in advanced-aged mice.
BibTeX
@inproceedings{collins2024systemic,
  author = {Craig Collins and Lam T. Khuat and Gail D. Sckisel and Logan V. Vick and Christine M. Minnar and Cordelia Dunai and Catherine T. Le and Brendan D. Curti and Marka R. Crittenden and Alexander Merleev and Quan Z. Sheng and Nelson J. Chao and Emanual Maverakis and Spencer R. Rosario and Arta M. Monjazeb and Bruce R. Blazar and Dan L. Longo and Robert J. Canter and William J. Murphy},
  title = {{Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipients}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1429912},
}
Figure